Document Detail

A prospective, randomized trial of topical hemostasis patch use following percutaneous coronary and peripheral intervention.
MedLine Citation:
PMID:  18987396     Owner:  NLM     Status:  MEDLINE    
The use of topical hemostasis patches has grown rapidly despite a paucity of evidence supporting their clinical utility. We performed a randomized, controlled trial to assess the efficacy of a topical hemostasis patch as a means to accelerate vascular hemostasis following percutaneous intervention. One hundred fifty (150) patients undergoing coronary or peripheral intervention through a 6 Fr femoral arterial sheath were randomized to sheath removal with either: (1) manual pressure and adjunctive use of a patch incorporating a polysaccharide based procoagulant material (SafeSeal Patch, Possis Medical Inc.); or (2) conventional manual pressure alone. Sheaths were removed when the activated clotting time (ACT) fell to < or = 250 seconds. Patients ambulated 2 hours after hemostasis was achieved. Time to hemostasis (duration of compression required until cessation of bleeding following sheath removal) was significantly lower in the hemostasis patch arm (11.8 +/- 3.6 vs. 13.8 +/- 5.8 minutes; p = 0.02). Attainment of hemostasis in < 15 minutes was also more likely among patients randomized to the hemostasis patch rather than manual compression alone (odds ratio = 2.5; 95% confidence intervals 1.2, 5.1; p = 0.014). The median time to ambulation (total duration from the end of the interventional procedure to ambulation) was significantly reduced among patients in the hemostasis patch arm (2.8 vs. 3.8 hours; p = 0.03). Bleeding complications were uncommon and did not differ between the study arms. In conclusion, this trial supports the concept that the polysaccharide-based SafeSeal Patch enhances access site hemostasis following endovascular intervention.
Craig R Narins; Wojciech Zareba; Vicki Rocco; Scott McNitt
Related Documents :
18793226 - Factor eight inhibitor bypassing activity (feiba) for refractory bleeding in cardiac su...
19826646 - Adrenaline injection plus argon plasma coagulation versus adrenaline injection plus hem...
7791066 - Low-dose intraocular tissue plasminogen activator treatment for traumatic total hyphema...
7796496 - Bleeding complications with the chimeric antibody to platelet glycoprotein iib/iiia int...
14763906 - Follow-up of low-risk patients with differentiated thyroid carcinoma: a european perspe...
21507656 - Outcome of posterior lumbar interbody fusion versus posterolateral fusion in lumbar deg...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of invasive cardiology     Volume:  20     ISSN:  1557-2501     ISO Abbreviation:  J Invasive Cardiol     Publication Date:  2008 Nov 
Date Detail:
Created Date:  2008-11-06     Completed Date:  2009-03-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8917477     Medline TA:  J Invasive Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  579-84     Citation Subset:  IM    
Division of Cardiology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Topical
Angioplasty, Transluminal, Percutaneous Coronary / adverse effects*
Coagulants / administration & dosage*
Early Ambulation
Femoral Artery*
Hemorrhage / prevention & control*
Hemostasis, Surgical / methods*
Middle Aged
Prospective Studies
Punctures / adverse effects*
Time Factors
Treatment Outcome
Reg. No./Substance:
Comment In:
J Invasive Cardiol. 2008 Nov;20(11):585-6   [PMID:  18987397 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Recanalization strategy for chronic total occlusions with tapered and stiff-tip guidewire. The resul...
Next Document:  A new method to quantify coronary calcification by intravascular ultrasound - the different patterns...